Minneapolis-American Medical Systems has received FDA approval for InhibiZone, an antibiotic surface treatment used on its AMS 700 series penile prostheses. The treatment is impregnated through a patented process into the tissue-contacting surfaces of the prostheses. In laboratory testing, the device elutes the drugs from the surface when exposed to a warm, moist environment, providing antibiotic action both on the surface and in a zone surrounding the treated device, according to the company.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.